Mirae Asset Launches its Global X China MedTech ETF in Hong Kong

News provided by

Mirae Asset Global Investments (Hong Kong) Limited

04 Aug, 2023, 09:00 CST

The launch of the Global X China MedTech ETF (2841) enriches Mirae Asset's suite of thematic ETFs
With a total of 27 ETFs listed in Hong Kong^[1], Mirae Asset is well-equipped to meet the increasing demand for innovative and thematic investment products

HONG KONG, Aug. 4, 2023 /PRNewswire/ -- Mirae Asset Global Investments (Hong Kong) Limited, (the "Firm" or "Mirae Asset") today announced the launch of its new Global X China MedTech ETF (2841) to be listed on the Hong Kong Stock Exchange. The fund, which begins trading on the Hong Kong Stock Exchange ("HKEX") today, offers access to Chinese companies that are at the forefront of medical technology, offering medical equipment, devices and consumables.

The launch of the Global X China MedTech ETF (2841) adds to the Firm's suite of thematic ETFs which are designed to provide investors with access to powerful and long-term disruptive trends. China's rapidly-growing medical device market, fueled by an ageing population, is poised to present growth opportunities. China's MedTech sector is expected to expand from RMB 1.2 trillion in 2022 to RMB 3.5 trillion by 2030, a growth at a CAGR of 14%.^[2] This ETF enables investors to gain exposure to diversified investment into various subsectors within the industry, including medical equipment, consumables, in-vitro diagnostics and consumer medtech.

Mr. Wanyoun CHO, Chief Executive Officer of Mirae Asset Global Investments (Hong Kong) Limited, said: "We are excited to enrich our suite of thematic ETFs that target growth, as Chinese innovators continue to redefine the domestic, regional as well as the global economy. Our new ETF offers investors a unique opportunity to tap into this dynamic market."

The Global X China MedTech ETF (2841) tracks the Solactive China MedTech Index. With this new ETF, the Firm now offers a total of 27 ETFs listed in Hong Kong, including 18 thematic ETFs, spanning a diverse array of investment capabilities from thematic growth, income, core to commodities.

About Mirae Asset Global Investments Group

Mirae Asset Global Investments Group (the "group") is an asset management organization with over US$214 billion in assets under management as of June 30, 2023^[3]. The organization provides a diverse range of investment products including mutual funds, exchange traded funds ("ETFs"), and alternatives. Operating out of 20 offices worldwide, the group has a global team of more than 1,000 employees, including more than 200 investment professionals.

The group's global ETF platform features a line-up of 525 ETFs that offer investors high quality and cost-efficient exposure to newly emerging investment themes and disruptive technologies in the global markets.^[4] The group's ETFs have combined assets under management of US$100 billion and are listed in Australia, Brazil, Canada, Colombia, Hong Kong, India, Japan, Korea, Vietnam, the United Kingdom, and the United States.^[5]

About Global X ETFs

Global X ETFs was founded in 2008. For more than a decade, our mission has been empowering investors with unexplored and intelligent solutions. Our product line-up features over 230 ETF strategies and over $45 billion in assets under management.^[6] While we are distinguished for our Thematic Growth, Income, and International Access ETFs, we also offer Core, Commodity, and Alpha funds to suit a wide range of investment objectives. Global X is a member of Mirae Asset Financial Group, a global leader in financial services, with more than US$548 billion in assets under management worldwide.^[7]

Mirae Asset Global Investments Hong Kong: https://www.am.miraeasset.com.hk/
Global X ETFs Hong Kong: www.globalxetfs.com.hk

[1] Source: Mirae Asset Global Investments, August 4, 2023.

[2] Source: UBS, March 2023.

[3] Source: Mirae Asset Global Investments, June 30, 2023.

[4] Source: Mirae Asset Global Investments, June 30, 2023.

[5] Source: Mirae Asset Global Investments, June 30, 2023.

[6] Source: Mirae Asset Global Investments, June 30, 2023.

[7] Source: Mirae Asset Financial Group, March 31, 2023.

Important Information

Investors should not base investment decisions on this material alone. Please refer to the Prospectus for details including product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

Global X China MedTech ETF's (the "Fund's") objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the Solactive China MedTech Index (the "Index").
The Index is a new index. The Index has minimal operating history by which investors can evaluate its previous performance. There can be no assurance as to the performance of the Index. The Fund may be riskier than other exchange traded funds tracking more established indices with longer operating history.
The Fund may invest in small and/or mid-capitalisation companies. The stock of small-capitalisation and mid-capitalisation companies may have lower liquidity and their prices are more volatile to adverse economic developments than those of larger capitalisation companies in general.
The Fund's investments are concentrated in companies in the medical technology industry. The value of the Fund may be more volatile than that of a fund having a more diverse portfolio of investments and may be more susceptible to adverse economic, political, policy, liquidity, tax, legal or regulatory event affecting the relevant industry.
Many of the companies with a high business exposure to a medical technology theme have a relatively short operating history. Rapid changes could render obsolete the products and services offered by these companies and cause severe or complete declines in the prices of the securities of those companies. Additionally, companies with medical technology themes may face dramatic and often unpredictable changes in growth rates and competition for the services of qualified personnel. They may potentially subject to (i) substantial government intervention in the technology industry (including restrictions on investment in internet and technology companies), (ii) complex laws and regulations including privacy, data protection, content regulation, intellectual property, competition, protection of minors, consumer protection and taxation, (iii) heavy and significant capital investment on research and development, (iv) risks of medical failure (including injury or death of patients), negligence or product liability claims, recall or withdrawal of products. These risks may result in adverse impact of the operating results of the companies.
The Mainland China is an emerging market. The Fund invests in Mainland Chinese companies which may involve increased risks and special considerations not typically associated with investment in more developed markets, such as liquidity risk, currency risks or control, political and economic uncertainties, legal and taxation risks, settlement risks, custody risk and the likelihood of a high degree of volatility. Securities exchanges in the Mainland Chinese markets typically have the right to suspend or limit trading in any security traded on the relevant exchange. The government or the regulators may also implement policies that may affect the financial markets. All these may have a negative impact on the Fund.
Listed companies on the ChiNext market and/or STAR Board are subject to higher fluctuation on stock prices and liquidity risk, over-valuation risk, less stringent regulation risk, delisting risk and concentration risk.
The Fund's synthetic replication strategy will involve investing up to 50% of its net asset value in financial derivative instruments ("FDIs"), mainly funded total return swap transaction(s) through one or more counterparty(ies). Risks associated with FDIs include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. FDIs are susceptible to price fluctuations and higher volatility, and may have large bid and offer spreads and no active secondary markets. The leverage element/component of an FDI can result in a loss significantly greater than the amount invested in the FDI by the Fund.
As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund. The borrower may fail to return the securities in a timely manner or at all. The Fund may suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund's ability in meeting delivery or payment obligations from redemption requests.
The trading price of the Shares on the Stock Exchange of Hong Kong is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund's Net Asset Value.
Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment.

Disclaimer

This document is for Hong Kong investors only. This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated services.

Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements.

Investment involves risk. Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Funds will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Funds and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.

Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (Hong Kong) Limited ("MAGIHK") are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.

Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGIHK as stipulated by local laws and regulations. This document is not directed to any person in any jurisdiction where the availability of this document is prohibited. Persons in respect of whom such prohibitions apply or persons other than those specified above must not access this document. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.

This document is issued by MAGIHK (Licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance). This document has not been reviewed by the Securities and Futures Commission or the applicable regulator in the jurisdiction in which this article is posted and no part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGIHK.

SOURCE Mirae Asset Global Investments (Hong Kong) Limited

Browse News Releases

All Multimedia

Mirae Asset Launches its Global X China MedTech ETF in Hong Kong

News provided by

Mirae Asset Expands Active ETF Product Line with the Launch of Global X India Sector Leader Active ETF (3084) and Global X Emerging Markets Asia Active ETF (3104)

Global X Hang Seng High Dividend Yield ETF Hits US$600 Million Milestone in AUM

Contact Cision

Products

About

My Services

Also from this source

Mirae Asset Expands Active ETF Product Line with the Launch of Global X India Sector Leader Active ETF (3084) and Global X Emerging Markets Asia Active ETF (3104)

Global X Hang Seng High Dividend Yield ETF Hits US$600 Million Milestone in AUM

Explore